Research Analysts Offer Predictions for Stoke Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a note issued to investors on Tuesday, April 9th. Leerink Partnrs analyst R. Li anticipates that the company will post earnings of ($0.54) per share for the quarter. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.28) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ Q4 2024 earnings at ($0.56) EPS.

Several other analysts also recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, March 26th. Canaccord Genuity Group lifted their target price on Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, March 26th. Wedbush lifted their target price on Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. JPMorgan Chase & Co. lifted their target price on Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research note on Tuesday, March 26th. Finally, TD Cowen raised Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Stoke Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $19.63.

Stoke Therapeutics Stock Down 5.4 %

STOK stock opened at $12.77 on Thursday. Stoke Therapeutics has a twelve month low of $3.35 and a twelve month high of $16.40. The stock has a market cap of $591.25 million, a P/E ratio of -5.39 and a beta of 0.77. The business’s 50-day moving average price is $8.01 and its 200-day moving average price is $5.71.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its holdings in Stoke Therapeutics by 1.4% during the 1st quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company’s stock valued at $1,320,000 after acquiring an additional 837 shares during the period. American International Group Inc. boosted its holdings in Stoke Therapeutics by 10.9% during the 2nd quarter. American International Group Inc. now owns 10,506 shares of the company’s stock valued at $139,000 after acquiring an additional 1,029 shares during the period. Great West Life Assurance Co. Can boosted its holdings in Stoke Therapeutics by 46.7% during the 1st quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock valued at $28,000 after acquiring an additional 1,078 shares during the period. Ensign Peak Advisors Inc purchased a new position in Stoke Therapeutics during the 1st quarter valued at $25,000. Finally, Point72 Hong Kong Ltd purchased a new position in Stoke Therapeutics during the 1st quarter valued at $27,000.

Insider Activity

In other news, General Counsel Jonathan Allan sold 5,126 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $13.20, for a total transaction of $67,663.20. Following the transaction, the general counsel now owns 2,598 shares of the company’s stock, valued at approximately $34,293.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, General Counsel Jonathan Allan sold 5,126 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $13.20, for a total transaction of $67,663.20. Following the transaction, the general counsel now owns 2,598 shares of the company’s stock, valued at approximately $34,293.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Stephen J. Tulipano sold 4,116 shares of the business’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $25,107.60. Following the transaction, the chief financial officer now owns 20,746 shares of the company’s stock, valued at approximately $126,550.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,741 shares of company stock valued at $223,115. 12.30% of the stock is currently owned by insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.